Popescu, N. C., King, C. R. & Kraus, M. H. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 4, 362–366 (1989).

Article  CAS  PubMed  Google Scholar 

Citri, A. & Yarden, Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7, 505–516 (2006).

Article  CAS  PubMed  Google Scholar 

Gutierrez, C. & Schiff, R. HER2: biology, detection, and clinical implications. Arch. Pathol. Lab. Med. 135, 55–62 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Oh, D. Y. & Bang, Y. J. HER2-targeted therapies — a role beyond breast cancer. Nat. Rev. Clin. Oncol. 17, 33–48 (2020).

Article  CAS  PubMed  Google Scholar 

Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023).

Article  CAS  PubMed  Google Scholar 

FDA. FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer#:~:Text=FDA%20grants%20accelerated%20approval%20to%20tucatinib%20with%20trastuzumab%20for%20colorectal%20cancer,-Share&Text=On%20January%2019%2C%202023%2C%20the,(Tukysa%2C%20Seagen%20Inc (2023).

FDA. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2 (2024).

Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010).

Article  CAS  PubMed  Google Scholar 

Jorgensen, J. T. & Hersom, M. HER2 as a prognostic marker in gastric cancer — a systematic analysis of data from the literature. J. Cancer 3, 137–144 (2012).

Article  PubMed  PubMed Central  Google Scholar 

Uchôa, B. C. D. M. et al. HER2-low and gastric cancer: a prognostic biomarker? J. Clin. Oncol. https://doi.org/10.1200/JCO.2021.39.15_suppl.e16086 (2021).

Riudavets, M., Sullivan, I., Abdayem, P. & Planchard, D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open 6, 100260 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshizawa, A. et al. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations. Lung Cancer 85, 373–378 (2014).

Article  PubMed  Google Scholar 

Connell, C. M. & Doherty, G. J. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open 2, e000279 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Cocco, E., Lopez, S., Santin, A. D. & Scaltriti, M. Prevalence and role of HER2 mutations in cancer. Pharmacol. Ther. 199, 188–196 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chmielecki, J. et al. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist 20, 7–12 (2015).

Article  CAS  PubMed  Google Scholar 

Li, B. T. et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N. Engl. J. Med. 386, 241–251 (2022).

Article  CAS  PubMed  Google Scholar 

Goto, K. et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-lung02 trial. J. Clin. Oncol. 41, 4852–4863 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

FDA. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung (2022).

Zabransky, D. J. et al. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc. Natl Acad. Sci. USA 112, E6205–E6214 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shigematsu, H. et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65, 1642–1646 (2005).

Article  CAS  PubMed  Google Scholar 

Greulich, H. et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc. Natl Acad. Sci. USA 109, 14476–14481 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meric-Bernstam, F. et al. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin. Cancer Res. 25, 2033–2041 (2019).

Article  CAS  PubMed  Google Scholar 

Xia, X., Gong, C., Zhang, Y. & Xiong, H. The history and development of HER2 inhibitors. Pharmaceuticals 16, 1450 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banerji, U. et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 20, 1124–1135 (2019).

Article  CAS  PubMed  Google Scholar 

Xu, Y. et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer 24, 913–925 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weisser, N. E. et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat. Commun. 14, 1394 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu, J. et al. KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer. Eur. J. Cancer 178, 1–12 (2023).

Article  PubMed  Google Scholar 

Back, J. et al. GBR1302: effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers. J. Clin. Oncol. https://doi.org/10.1200/JCO.2018.36.15_suppl.120 (2018).

Rudnik, M. et al. Combined investigation of anti-tumor efficacy and liver safety of bispecific T cell engagers in immune-competent high-throughput co-culturing platform. Cancer Res. 83, 2747 (2023).

Article  Google Scholar 

Kim, K. M. et al. Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force. Asia Pac. J. Clin. Oncol. 10, 297–307 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Valtorta, E. et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod. Pathol. 28, 1481–1491 (2015).

Article  CAS  PubMed  Google Scholar 

Buza, N., English, D. P., Santin, A. D. & Hui, P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod. Pathol. 26, 1605–1612 (2013).

Article  CAS  PubMed  Google Scholar 

Lamarca, A. et al. The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. PLoS ONE 13, e0206007 (2018).

Article  PubMed  PubMed Central